Symbols / LEXX $0.97 +2.19% Lexaria Bioscience Corp.
LEXX Chart
About
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Fundamentals
Scroll to Statements| Market Cap | 24.04M | Enterprise Value | 18.48M | Income | -9.53M | Sales | 368.00K | Book/sh | 0.27 | Cash/sh | 0.21 |
| Dividend Yield | — | Payout | 0.00% | Employees | 7 | IPO | — | P/E | — | Forward P/E | -2.49 |
| PEG | — | P/S | 65.34 | P/B | 3.66 | P/C | — | EV/EBITDA | -2.02 | EV/Sales | 50.21 |
| Quick Ratio | 24.74 | Current Ratio | 26.88 | Debt/Eq | 1.52 | LT Debt/Eq | — | EPS (ttm) | -0.47 | EPS next Y | -0.39 |
| EPS Growth | — | Revenue Growth | -88.50% | Earnings | 2026-04-13 | ROA | -75.98% | ROE | -147.07% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | -72.60% | Profit Margin | 0.00% | Shs Outstand | 24.79M | Shs Float | 23.44M | Short Float | 1.18% |
| Short Ratio | 1.82 | Short Interest | — | 52W High | 1.69 | 52W Low | 0.46 | Beta | 0.48 | Avg Volume | 175.47K |
| Volume | 116.19K | Target Price | $3.75 | Recom | None | Prev Close | $0.95 | Price | $0.97 | Change | 2.19% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-26 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-07-29 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-07-01 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-01-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-18 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-10 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2024-03-05 | main | Maxim Group | Buy → Buy | $12 |
| 2023-07-21 | init | Maxim Group | — → Buy | $2 |
- Weight-loss pill hit 600,000 scripts in 2 months as oral market builds - Stock Titan ue, 21 Apr 2026 13
- Lexaria Bioscience (LEXX) Stock Profit Outlook (Trend Weakens) 2026-04-20 - Portfolio Management - UBND thành phố Hải Phòng Mon, 20 Apr 2026 17
- Is Lexaria Bioscience (LEXX) stock an investment worth exploring (Eye on Rally) 2026-04-18 - Volume Leaders - Cổng thông tin điện tử tỉnh Tây Ninh Sat, 18 Apr 2026 22
- Is Lexaria Bioscience (LEXX) stock an investment worth exploring (Eye on Rally) 2026-04-18 - Social Trading - Cổng thông tin điện tử Tỉnh Sơn La Sat, 18 Apr 2026 22
- Can Lexaria Bioscience (NASDAQ:LEXX) Afford To Invest In Growth? - simplywall.st Sat, 18 Apr 2026 13
- LEXARIA BIOSCIENCE ($LEXX) Releases Q2 2026 Earnings - Quiver Quantitative Mon, 13 Apr 2026 17
- A 5-week human trial will test Lexaria's oral GLP-1 against Wegovy - Stock Titan Wed, 01 Apr 2026 07
- LEXX Stock Analysis: Lexaria Bioscience Corp posts 20 percent daily gain to 1.04 - UBND thành phố Hải Phòng Fri, 03 Apr 2026 07
- A third oral GLP-1 wins FDA approval, and Lexaria sees an opening - Stock Titan ue, 07 Apr 2026 07
- Lexaria lines up rat study to test drug formulas for new patents - Stock Titan Wed, 15 Apr 2026 13
- Biotech tests new oral GLP-1 formulas against Wegovy tablets - Stock Titan Wed, 04 Mar 2026 08
- Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan ue, 30 Dec 2025 08
- Lexaria (NASDAQ: LEXX) prices $3.5M direct stock offering, adds 5-year warrants - Stock Titan Mon, 15 Dec 2025 08
- Weight-loss pills over shots? Lexaria says pharma talks are underway - Stock Titan ue, 24 Mar 2026 07
- Drug delivery firm Lexaria now holds 60 patents in nicotine, hypertension, epilepsy, diabetes - Stock Titan hu, 22 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.71
+52.05%
|
0.46
+105.24%
|
0.23
-11.43%
|
0.26
|
| Operating Revenue |
|
0.71
+52.34%
|
0.46
+142.65%
|
0.19
+13.67%
|
0.17
|
| Cost Of Revenue |
|
0.00
-43.59%
|
0.00
-84.69%
|
0.03
-56.15%
|
0.07
|
| Reconciled Cost Of Revenue |
|
0.00
-43.59%
|
0.00
-84.69%
|
0.03
-56.15%
|
0.07
|
| Gross Profit |
|
0.70
+53.05%
|
0.46
+135.97%
|
0.19
+6.08%
|
0.18
|
| Operating Expense |
|
12.58
+102.56%
|
6.21
-7.67%
|
6.73
-1.09%
|
6.80
|
| Research And Development |
|
8.24
+249.02%
|
2.36
-35.62%
|
3.67
+98.99%
|
1.84
|
| Selling General And Administration |
|
4.35
+12.80%
|
3.85
+25.80%
|
3.06
-38.26%
|
4.96
|
| General And Administrative Expense |
|
4.35
+12.80%
|
3.85
+25.80%
|
3.06
-38.26%
|
4.96
|
| Other Gand A |
|
4.35
+12.80%
|
3.85
+25.80%
|
3.06
-38.26%
|
4.96
|
| Total Expenses |
|
12.59
+102.44%
|
6.22
-8.03%
|
6.76
-1.66%
|
6.87
|
| Operating Income |
|
-11.88
-106.51%
|
-5.75
+11.95%
|
-6.53
+1.28%
|
-6.62
|
| Total Operating Income As Reported |
|
-11.88
-106.51%
|
-5.75
+11.95%
|
-6.53
+1.28%
|
-6.62
|
| EBITDA |
|
-11.79
-107.73%
|
-5.68
+11.14%
|
-6.39
+1.96%
|
-6.52
|
| Normalized EBITDA |
|
-11.76
-109.72%
|
-5.61
+9.08%
|
-6.17
-7.22%
|
-5.75
|
| Reconciled Depreciation |
|
0.09
+15.33%
|
0.08
-47.62%
|
0.15
+41.55%
|
0.10
|
| EBIT |
|
-11.88
-106.51%
|
-5.75
+11.95%
|
-6.53
+1.28%
|
-6.62
|
| Total Unusual Items |
|
-0.03
+51.72%
|
-0.07
+68.50%
|
-0.22
+71.01%
|
-0.76
|
| Total Unusual Items Excluding Goodwill |
|
-0.03
+51.72%
|
-0.07
+68.50%
|
-0.22
+71.01%
|
-0.76
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-11.90
-105.37%
|
-5.80
+13.05%
|
-6.66
+8.31%
|
-7.27
|
| Pretax Income |
|
-11.91
-105.06%
|
-5.81
+13.47%
|
-6.71
+9.09%
|
-7.38
|
| Net Non Operating Interest Income Expense |
|
0.00
-78.92%
|
0.01
-66.87%
|
0.04
|
0.00
|
| Net Interest Income |
|
0.00
-78.92%
|
0.01
-66.87%
|
0.04
|
0.00
|
| Interest Income Non Operating |
|
0.00
-78.92%
|
0.01
-66.87%
|
0.04
|
0.00
|
| Interest Income |
|
0.00
-78.92%
|
0.01
-66.87%
|
0.04
|
0.00
|
| Other Income Expense |
|
-0.03
+51.72%
|
-0.07
+68.50%
|
-0.22
+71.01%
|
-0.76
|
| Gain On Sale Of Security |
|
-0.03
+51.72%
|
-0.07
+68.50%
|
-0.22
+71.01%
|
-0.76
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.91
-105.06%
|
-5.81
+13.47%
|
-6.71
+9.09%
|
-7.38
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.90
-105.37%
|
-5.80
+13.05%
|
-6.66
+8.31%
|
-7.27
|
| Net Income From Continuing And Discontinued Operation |
|
-11.90
-105.37%
|
-5.80
+13.05%
|
-6.66
+8.31%
|
-7.27
|
| Net Income Continuous Operations |
|
-11.91
-105.06%
|
-5.81
+13.47%
|
-6.71
+9.09%
|
-7.38
|
| Net Income Discontinuous Operations |
|
—
|
—
|
—
|
0.00
|
| Minority Interests |
|
0.01
-27.92%
|
0.01
-72.06%
|
0.05
-58.34%
|
0.11
|
| Normalized Income |
|
-11.87
-107.29%
|
-5.73
+11.14%
|
-6.44
+0.95%
|
-6.50
|
| Net Income Common Stockholders |
|
-11.90
-105.37%
|
-5.80
+13.05%
|
-6.66
+8.31%
|
-7.27
|
| Diluted EPS |
|
-0.66
-40.43%
|
-0.47
+53.47%
|
-1.01
+18.55%
|
-1.24
|
| Basic EPS |
|
-0.66
-40.43%
|
-0.47
+53.47%
|
-1.01
+18.55%
|
-1.24
|
| Basic Average Shares |
|
18.00
+45.34%
|
12.38
+87.24%
|
6.61
+12.38%
|
5.89
|
| Diluted Average Shares |
|
18.00
+45.34%
|
12.38
+87.24%
|
6.61
+12.38%
|
5.89
|
| Diluted NI Availto Com Stockholders |
|
-11.90
-105.37%
|
-5.80
+13.05%
|
-6.66
+8.31%
|
-7.27
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Total Assets |
|
4.18
-52.92%
|
8.87
+187.54%
|
3.08
-60.63%
|
7.83
|
| Current Assets |
|
3.47
-56.09%
|
7.90
+267.14%
|
2.15
-69.17%
|
6.98
|
| Cash Cash Equivalents And Short Term Investments |
|
1.97
-69.99%
|
6.56
+343.63%
|
1.48
-76.01%
|
6.16
|
| Cash And Cash Equivalents |
|
1.80
-72.27%
|
6.50
+380.72%
|
1.35
-76.74%
|
5.81
|
| Cash Financial |
|
1.80
-72.27%
|
6.50
+380.72%
|
1.35
-76.74%
|
5.81
|
| Other Short Term Investments |
|
0.17
+196.31%
|
0.06
-55.58%
|
0.13
-63.83%
|
0.35
|
| Receivables |
|
0.37
+138.45%
|
0.15
+21.94%
|
0.13
-37.22%
|
0.20
|
| Accounts Receivable |
|
—
|
—
|
0.05
-39.58%
|
0.08
|
| Other Receivables |
|
0.17
+107.14%
|
0.08
+240.98%
|
0.02
-33.86%
|
0.04
|
| Taxes Receivable |
|
0.19
+175.78%
|
0.07
-30.94%
|
0.10
+21.26%
|
0.08
|
| Inventory |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Raw Materials |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Prepaid Assets |
|
1.13
-4.66%
|
1.19
+117.24%
|
0.55
-5.20%
|
0.58
|
| Total Non Current Assets |
|
0.71
-27.12%
|
0.97
+3.97%
|
0.93
+8.92%
|
0.86
|
| Net PPE |
|
0.33
-14.02%
|
0.39
-7.60%
|
0.42
+14.58%
|
0.37
|
| Gross PPE |
|
0.90
-0.37%
|
0.91
+1.16%
|
0.90
+19.90%
|
0.75
|
| Accumulated Depreciation |
|
-0.57
-9.90%
|
-0.52
-8.93%
|
-0.48
-25.05%
|
-0.38
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Other Properties |
|
0.54
-0.62%
|
0.55
+1.95%
|
0.53
+38.55%
|
0.39
|
| Leases |
|
0.26
+0.00%
|
0.26
+0.00%
|
0.26
+0.00%
|
0.26
|
| Goodwill And Other Intangible Assets |
|
0.31
-40.42%
|
0.52
+11.68%
|
0.46
-5.29%
|
0.49
|
| Other Intangible Assets |
|
0.31
-40.42%
|
0.52
+11.68%
|
0.46
-5.29%
|
0.49
|
| Non Current Accounts Receivable |
|
0.06
+0.69%
|
0.06
+30.92%
|
0.05
|
—
|
| Total Liabilities Net Minority Interest |
|
1.57
+30.08%
|
1.21
+199.26%
|
0.40
+100.51%
|
0.20
|
| Current Liabilities |
|
1.49
+35.84%
|
1.10
+310.64%
|
0.27
+37.98%
|
0.19
|
| Payables And Accrued Expenses |
|
1.46
+37.19%
|
1.07
+344.45%
|
0.24
+58.43%
|
0.15
|
| Payables |
|
1.46
+37.19%
|
1.07
+344.45%
|
0.24
+58.43%
|
0.15
|
| Accounts Payable |
|
1.37
+29.04%
|
1.06
+370.09%
|
0.23
+87.30%
|
0.12
|
| Other Payable |
|
0.08
|
—
|
—
|
0.06
|
| Total Tax Payable |
|
0.02
+152.18%
|
0.01
-42.78%
|
0.01
-52.39%
|
0.03
|
| Income Tax Payable |
|
—
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.03
+8.45%
|
0.03
+0.91%
|
0.03
-34.74%
|
0.04
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Other Current Borrowings |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.03
+8.45%
|
0.03
+0.91%
|
0.03
-34.74%
|
0.04
|
| Current Deferred Liabilities |
|
0.00
-100.00%
|
0.00
|
0.00
|
—
|
| Current Deferred Revenue |
|
0.00
-100.00%
|
0.00
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.08
-27.82%
|
0.11
-19.72%
|
0.14
+1739.93%
|
0.01
|
| Long Term Debt And Capital Lease Obligation |
|
0.08
-27.82%
|
0.11
-19.72%
|
0.14
+1739.93%
|
0.01
|
| Long Term Capital Lease Obligation |
|
0.08
-27.82%
|
0.11
-19.72%
|
0.14
+1739.93%
|
0.01
|
| Stockholders Equity |
|
2.99
-62.80%
|
8.04
+164.00%
|
3.04
-61.70%
|
7.95
|
| Common Stock Equity |
|
2.99
-62.80%
|
8.04
+164.00%
|
3.04
-61.70%
|
7.95
|
| Capital Stock |
|
0.02
+23.71%
|
0.02
+95.40%
|
0.01
+35.96%
|
0.01
|
| Common Stock |
|
0.02
+23.71%
|
0.02
+95.40%
|
0.01
+35.96%
|
0.01
|
| Share Issued |
|
19.56
+23.71%
|
15.81
+95.39%
|
8.09
+35.97%
|
5.95
|
| Ordinary Shares Number |
|
19.56
+23.71%
|
15.81
+95.39%
|
8.09
+35.97%
|
5.95
|
| Additional Paid In Capital |
|
66.50
+11.58%
|
59.60
+22.13%
|
48.80
+3.74%
|
47.04
|
| Retained Earnings |
|
-63.46
-23.08%
|
-51.56
-12.66%
|
-45.76
-17.05%
|
-39.10
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.07
-254.94%
|
-0.02
|
0.00
|
—
|
| Minority Interest |
|
-0.39
-2.54%
|
-0.38
-3.66%
|
-0.36
-15.05%
|
-0.32
|
| Other Equity Adjustments |
|
-0.07
-254.94%
|
-0.02
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
2.60
-66.02%
|
7.66
+185.78%
|
2.68
-64.89%
|
7.63
|
| Total Capitalization |
|
2.99
-62.80%
|
8.04
+164.00%
|
3.04
-61.70%
|
7.95
|
| Working Capital |
|
1.97
-70.95%
|
6.80
+260.96%
|
1.88
-72.23%
|
6.78
|
| Invested Capital |
|
2.99
-62.80%
|
8.04
+164.00%
|
3.04
-61.70%
|
7.95
|
| Total Debt |
|
0.11
-20.42%
|
0.14
-16.22%
|
0.16
+228.01%
|
0.05
|
| Capital Lease Obligations |
|
0.11
-20.42%
|
0.14
-16.22%
|
0.16
+228.01%
|
0.05
|
| Net Tangible Assets |
|
2.68
-64.34%
|
7.52
+191.29%
|
2.58
-65.40%
|
7.46
|
| Tangible Book Value |
|
2.68
-64.34%
|
7.52
+191.29%
|
2.58
-65.40%
|
7.46
|
| Dueto Related Parties Current |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.45
-110.74%
|
-4.96
+15.68%
|
-5.88
-20.53%
|
-4.88
|
| Cash Flow From Continuing Operating Activities |
|
-10.45
-110.74%
|
-4.96
+15.68%
|
-5.88
-20.53%
|
-4.88
|
| Net Income From Continuing Operations |
|
-11.91
-105.06%
|
-5.81
+13.47%
|
-6.71
+9.09%
|
-7.38
|
| Depreciation Amortization Depletion |
|
0.09
+15.33%
|
0.08
-47.62%
|
0.15
+41.55%
|
0.10
|
| Depreciation |
|
—
|
—
|
—
|
0.14
|
| Depreciation And Amortization |
|
0.09
+15.33%
|
0.08
-47.62%
|
0.15
+41.55%
|
0.10
|
| Other Non Cash Items |
|
0.04
-5.60%
|
0.04
-10.31%
|
0.04
-96.48%
|
1.24
|
| Stock Based Compensation |
|
0.86
+74.61%
|
0.49
+188.90%
|
0.17
-77.36%
|
0.75
|
| Asset Impairment Charge |
|
0.25
+277.10%
|
0.07
-38.56%
|
0.11
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-0.01
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
0.03
-51.72%
|
0.07
-68.50%
|
0.22
-71.01%
|
0.76
|
| Change In Working Capital |
|
0.20
+83.54%
|
0.11
-25.62%
|
0.14
+140.76%
|
-0.35
|
| Change In Receivables |
|
-0.21
-323.83%
|
-0.05
-290.54%
|
0.03
+119.30%
|
-0.14
|
| Changes In Account Receivables |
|
-0.21
-501.62%
|
-0.04
-233.96%
|
0.03
+119.30%
|
-0.14
|
| Change In Inventory |
|
—
|
0.00
-100.00%
|
0.04
+2276.30%
|
-0.00
|
| Change In Prepaid Assets |
|
0.06
+108.63%
|
-0.64
-2238.35%
|
0.03
+111.64%
|
-0.26
|
| Change In Payables And Accrued Expense |
|
0.40
-52.01%
|
0.83
+833.95%
|
0.09
+94.48%
|
0.05
|
| Change In Payable |
|
—
|
0.83
+833.95%
|
0.09
+94.48%
|
0.05
|
| Change In Account Payable |
|
—
|
0.83
+833.95%
|
0.09
+74.45%
|
0.05
|
| Change In Other Working Capital |
|
-0.00
-200.00%
|
0.00
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.04
-11.48%
|
-0.03
+25.75%
|
-0.04
|
0.00
|
| Investing Cash Flow |
|
-0.24
-28.85%
|
-0.19
-11.20%
|
-0.17
+6.11%
|
-0.18
|
| Cash Flow From Continuing Investing Activities |
|
-0.24
-28.85%
|
-0.19
-11.20%
|
-0.17
+6.11%
|
-0.18
|
| Net PPE Purchase And Sale |
|
-0.02
+42.70%
|
-0.04
-27.46%
|
-0.03
+31.40%
|
-0.05
|
| Purchase Of PPE |
|
-0.02
+42.70%
|
-0.04
-27.46%
|
-0.03
+31.40%
|
-0.05
|
| Capital Expenditure |
|
-0.10
+47.11%
|
-0.19
-11.20%
|
-0.17
+6.11%
|
-0.18
|
| Net Investment Purchase And Sale |
|
-0.14
|
0.00
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.08
+48.41%
|
-0.15
-7.16%
|
-0.14
-3.36%
|
-0.13
|
| Purchase Of Intangibles |
|
-0.08
+48.41%
|
-0.15
|
—
|
-0.13
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-0.05
|
| Financing Cash Flow |
|
6.05
-41.39%
|
10.32
+548.86%
|
1.59
+3664.42%
|
-0.04
|
| Cash Flow From Continuing Financing Activities |
|
6.05
-41.39%
|
10.32
+548.86%
|
1.59
+3664.42%
|
-0.04
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.04
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.04
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.04
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.04
|
| Net Common Stock Issuance |
|
6.05
+43.66%
|
4.21
+164.74%
|
1.59
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
6.11
|
0.00
|
0.00
|
| Changes In Cash |
|
-4.65
-189.93%
|
5.17
+215.84%
|
-4.46
+12.61%
|
-5.10
|
| Effect Of Exchange Rate Changes |
|
-0.05
-154.94%
|
-0.02
|
0.00
|
—
|
| Beginning Cash Position |
|
6.50
+380.72%
|
1.35
-76.74%
|
5.81
-46.75%
|
10.92
|
| End Cash Position |
|
1.80
-72.27%
|
6.50
+380.72%
|
1.35
-76.74%
|
5.81
|
| Free Cash Flow |
|
-10.55
-104.95%
|
-5.15
+14.93%
|
-6.05
-19.58%
|
-5.06
|
| Income Tax Paid Supplemental Data |
|
—
|
0.01
+22.25%
|
0.01
+71.77%
|
0.00
|
| Common Stock Issuance |
|
6.05
+43.66%
|
4.21
+164.74%
|
1.59
|
0.00
|
| Issuance Of Capital Stock |
|
6.05
+43.66%
|
4.21
+164.74%
|
1.59
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-04-13 View
- 42026-03-18 View
- 8-K2026-02-06 View
- 8-K2026-01-28 View
- 10-Q2026-01-13 View
- 8-K2025-12-16 View
- 10-K2025-11-28 View
- 8-K2025-09-29 View
- 8-K2025-09-25 View
- 42025-07-30 View
- 42025-07-30 View
- 42025-07-30 View
- 42025-07-30 View
- 42025-07-30 View
- 10-Q2025-07-14 View
- 8-K2025-06-12 View
- 42025-05-16 View
- 42025-05-16 View
- 42025-05-16 View
- 42025-05-16 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|